Purpose: Bortezomib is a peptide boronic acid inhibitor of the proteasome developed for
cancer therapy. The compound is being evaluated currently in Phase II and III clinical trials …

New options are needed for the treatment of B-cell chronic lymphocytic leukemia (CLL).
Proteasome inhibitors represent a potential therapeutic strategy. One such agent …

Proteasome inhibitors are potent inducers of apoptosis in isolated lymphocytes from patients
with chronic lymphocytic leukemia (CLL). However, the reversible proteasome inhibitor …

Objective: The anti‐tumour in vitro activity of proteasome inhibitor bortezomib (PS‐341,
VELCADE) in combination with purine nucleoside analogues, cladribine (2‐CdA) and …

Inhibitor of proteasome, bortezomib (BOR), although highly active in vitro, showed
unexpectedly low efficacy in vivo in patients with B-CLL when used alone. We studied the in …

The proteasome plays a critical role in the regulation of many cellular processes, including
the cell cycle and tumor growth. The proteasome inhibitor bortezomib has recently been …

次に, Bortezomib 処理により ATL 細胞株が apoptosis を誘導されるかどうか TUNELassay
を用いて検討したところ, 薬剤処理 24 時間後に apoptosis を認めた. 更にカスペース阻害剤を …

The ubiquitin–proteasome system plays a crucial role in eukaryotic cells in maintaining
protein homeostasis. Through the disruption of a variety of pathways and cell cycle …

The multiple cellular targets affected by proteasome inhibition implicate a potential role for
bortezomib, a first-in-class proteasome inhibitor, in enhancing antitumor activities in …

The proteasome, which plays a pivotal role in the control of many cell cycle–regulatory
processes, has become the focus of new approaches to the treatment of cancer, including B …